Vera Golder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/330764/publications.pdf

Version: 2024-02-01

516561 580701 25 27 756 16 citations h-index g-index papers 27 27 27 839 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Research and Therapy, 2017, 19, 62.	1.6	100
2	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus, 2013, 22, 1425-1430.	0.8	65
3	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatology, The, 2019, 1, e95-e102.	2.2	65
4	Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus, 2018, 27, 501-506.	0.8	57
5	Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 629-633.	0.5	53
6	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatology, The, 2020, 2, e24-e30.	2.2	45
7	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 2016, 18, 260.	1.6	44
8	Ankylosing spondylitis: an update. Australian Family Physician, 2013, 42, 780-4.	0.5	39
9	Systemic lupus erythematosus: an update. Medical Journal of Australia, 2017, 206, 215-220.	0.8	38
10	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatology, The, 2019, 1, e103-e110.	2.2	38
11	Treatment targets in SLE: remission and low disease activity state. Rheumatology, 2020, 59, v19-v28.	0.9	26
12	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	0.9	24
13	Disseminated Enteroviral Infection Associated with Obinutuzumab. Emerging Infectious Diseases, 2015, 21, 1661-1663.	2.0	21
14	Autonomic cardiovascular control in hypotensive critically ill preterm infants is impaired during the first days of life. Early Human Development, 2013, 89, 419-423.	0.8	19
15	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 1289-1295.	1.5	19
16	Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Seminars in Arthritis and Rheumatism, 2017, 46, 798-803.	1.6	18
17	â€`Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosusâ€"a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	1.6	17
18	Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatology, The, 2021, 3, e595-e603.	2.2	13

#	Article	IF	Citations
19	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	0.9	12
20	Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Lupus, 2019, 28, 1669-1677.	0.8	11
21	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational <i>study</i> . Rheumatology, 2021, 60, 5185-5193.	0.9	9
22	Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology, 2022, 62, 190-199.	0.9	7
23	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. Journal of Rheumatology, 2017, 44, 271-278.	1.0	6
24	Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?. Journal of Rheumatology, 2019, 46, 1256-1258.	1.0	6
25	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. Rheumatology, 2022, 61, 1341-1353.	0.9	4
26	Defining remission in systemic lupus erythematosus: still elusive?. Lancet Rheumatology, The, 2019, 1, e137-e138.	2,2	0
27	Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study. Arthritis Research and Therapy, 2022, 24, .	1.6	0